Dry Age-Related Macular Degeneration Market to Reach USD 22.64 Billion by 2031, Significant Growth Projected for Dry AMD Treatment and Management Beállítások

[healthtechkatta]

The Dry Age-Related Macular Degeneration (AMD) market, valued at USD 12.03 billion in 2023, is anticipated to grow to USD 22.64 billion by 2031. This growth represents a compound annual growth rate (CAGR) of 8.22% during the forecast period from 2024 to 2031.

Drivers Behind Market Expansion

The increase in market size can be attributed to the rising prevalence of dry AMD, particularly among the aging population. As the global demographic shifts towards an older age, the demand for effective treatments and management solutions for dry AMD is expected to rise. Advances in research and development, along with a growing emphasis on early diagnosis and intervention, are also contributing to market growth.

Innovations and Therapeutic Advances

Recent innovations in therapeutic options and diagnostic tools are playing a crucial role in the market’s expansion. Companies are investing in novel therapies, including drugs and supplements, that aim to slow the progression of dry AMD and improve patients' quality of life. Enhanced imaging technologies and genetic research are further driving advancements in treatment strategies.

Regional and Market Insights

North America dominates the dry AMD market due to the high prevalence of the condition and advanced healthcare infrastructure. However, the Asia-Pacific region is projected to experience significant growth, driven by increasing awareness, improved healthcare systems, and rising disposable incomes.

Future Outlook

The dry AMD market is set for substantial growth, driven by ongoing research, technological advancements, and an increasing patient population. As the demand for effective management and treatment options rises, the market is expected to continue its upward trajectory, reaching USD 22.64 billion by 2031.